Skip to content
Homepage
Author:
Virax BioLabs Group Limited
Posted Date:
July 16, 2026
Virax Biolabs’ CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
Virax BioLabs Group Limited
July 16, 2026
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Virax BioLabs Group Limited
July 10, 2026
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Virax BioLabs Group Limited
July 9, 2026
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
Virax BioLabs Group Limited
July 9, 2026
Virax Biolabs Group Limited Announces 1-for-25 Share Consolidation
Virax BioLabs Group Limited
June 24, 2026
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
Virax BioLabs Group Limited
May 26, 2026
Virax Biolabs’ CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
Virax BioLabs Group Limited
May 6, 2026
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
Virax BioLabs Group Limited
May 4, 2026
